Scripture-Adams Deirdre D, Brooks David G, Korin Yael D, Zack Jerome A
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
J Virol. 2002 Dec;76(24):13077-82. doi: 10.1128/jvi.76.24.13077-13082.2002.
Latent human immunodeficiency virus type 1 (HIV-1) persists even in patients treated with antiretroviral therapy. New treatment strategies are therefore needed to eradicate this latent viral reservoir without reducing immune cell function. We characterize the interleukin-7 (IL-7)-induced stimulation of primary human T cells and thymocytes and demonstrate, using the SCID-hu model, that IL-7 induces substantial expression of latent HIV while having minimal effects on the cell phenotype. Thus, IL-7 is a viable candidate to activate expression of latent HIV and may facilitate immune clearance of latently infected cells.
即使在接受抗逆转录病毒疗法治疗的患者中，潜伏的1型人类免疫缺陷病毒（HIV-1）仍会持续存在。因此，需要新的治疗策略来根除这种潜伏的病毒库，同时又不降低免疫细胞功能。我们对白细胞介素-7（IL-7）诱导的原代人T细胞和胸腺细胞刺激进行了表征，并使用SCID-hu模型证明，IL-7可诱导潜伏HIV的大量表达，而对细胞表型的影响最小。因此，IL-7是激活潜伏HIV表达的可行候选物，可能有助于对潜伏感染细胞的免疫清除。
